Pranlukast Antagonizes CD49f and Reduces Sternness in Triple-Negative Breast Cancer Cells by Velazquez-Quesada, Ines et al.
 
 
 University of Groningen
Pranlukast Antagonizes CD49f and Reduces Sternness in Triple-Negative Breast Cancer
Cells
Velazquez-Quesada, Ines; Ruiz-Moreno, Angel J.; Casique-Aguirre, Diana; Aguirre-Alvarado,
Charmina; Cortes-Mendoza, Fabiola; de la Fuente-Granada, Marisol; Garcia-Perez, Carlos;
Perez-Tapia, Sonia M.; Gonzalez-Arenas, Aliesha; Segura-Cabrera, Aldo
Published in:
Drug Design, Development and Therapy
DOI:
10.2147/DDDT.S247730
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Velazquez-Quesada, I., Ruiz-Moreno, A. J., Casique-Aguirre, D., Aguirre-Alvarado, C., Cortes-Mendoza,
F., de la Fuente-Granada, M., Garcia-Perez, C., Perez-Tapia, S. M., Gonzalez-Arenas, A., Segura-
Cabrera, A., & Velasco-Velazquez, M. A. (2020). Pranlukast Antagonizes CD49f and Reduces Sternness in
Triple-Negative Breast Cancer Cells. Drug Design, Development and Therapy, 14, 1799-1811.
https://doi.org/10.2147/DDDT.S247730
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
OR I G I N A L R E S E A R C H
Pranlukast Antagonizes CD49f and Reduces
Stemness in Triple-Negative Breast Cancer Cells
This article was published in the following Dove Press journal:
Drug Design, Development and Therapy
Inés Velázquez-Quesada1,2




Marisol de la Fuente-Granada6
Carlos García-Pérez7




1Department of Pharmacology, School of
Medicine, Universidad Nacional Autónoma
de México, Mexico City, Mexico; 2Research
and Development in Bioprocess Unit,
National School of Biological Sciences,
Instituto Politécnico Nacional, Mexico City,
Mexico; 3Graduate Program in Biomedical
Sciences, Universidad Nacional Autónoma
de México, Mexico City, Mexico;
4Department ofDrugDesign,Graduate School of
Science and Engineering, University of Groningen
(RUG), Groningen, The Netherlands; 5Graduate
Program in Biochemical Sciences, Universidad
Nacional Autónoma de México, Mexico City,
Mexico; 6Department of Genomic Medicine and
Environmental Toxicology, Institute for Biomedical
Research, Universidad Nacional Autónoma de
México, Mexico City, Mexico; 7Center for
Genomic Biotechnology, Instituto Politécnico
Nacional, Reynosa, Tamaulipas, Mexico; 8National
Laboratory for Specialized Services of
Investigation, Development and Innovation (I+D
+i) for Pharma Chemicals and Biotechnological
Products, LANSEIDI-FarBiotec-CONACyT,
Mexico City, Mexico; 9European Molecular
Biology Laboratory, European Bioinformatics
Institute, Hinxton, UK; 10Peripherical Unit for
Research in Translational Biomedicine, School of
Medicine, Universidad Nacional Autónoma de
México, Mexico City, Mexico
Introduction: Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy
response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance
of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast
CSCs. In the present study, we aimed to repurpose drugs as CD49f antagonists.
Materials and Methods: We performed consensus molecular docking using a subdomain
of CD49f that is critical for heterodimerization and a collection of pharmochemicals clini-
cally tested. Molecular dynamics simulations were employed to further characterize drug-
target binding. Using MDA-MB-231 cells, we evaluated the effects of potential CD49f
antagonists on 1) cell adhesion to laminin; 2) mammosphere formation; and 3) cell viability.
We analyzed the effects of the drug with better CSC-selectivity on the activation of CD49f-
downstream signaling by Western blot (WB) and co-immunoprecipitation. Expressions of the
stem cell markers CD44 and SOX2 were analyzed by flow cytometry and WB, respectively.
Transactivation of SOX2 promoter was evaluated by luciferase reporter assays. Changes in
the number of CSCs were assessed by limiting-dilution xenotransplantation.
Results: Pranlukast, a drug used to treat asthma, bound to CD49f in silico and inhibited the
adhesion of CD49f+ MDA-MB-231 cells to laminin, indicating that it antagonizes CD49f-
containing integrins. Molecular dynamics analysis showed that pranlukast binding induces con-
formational changes inCD49f that affect its interactionwith β1-integrin subunit and constrained the
conformational dynamics of the heterodimer. Pranlukast decreased the clonogenicity of breast
cancer cells on mammosphere formation assay but had no impact on the viability of bulk tumor
cells. Brief exposure of MDA-MB-231 cells to pranlukast altered CD49f-dependent signaling,
reducing focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) activation. Further,
pranlukast-treated cells showed decreased CD44 and SOX2 expression, SOX2 promoter transacti-
vation, and in vivo tumorigenicity, supporting that this drug reduces the frequency of CSC.
Conclusion: Our results support the function of pranlukast as a CD49f antagonist that
reduces the CSC population in triple-negative breast cancer cells. The pharmacokinetics and
toxicology of this drug have already been established, rendering a potential adjuvant therapy
for breast cancer patients.
Keywords: CD49f, alpha6 integrin, breast cancer stem cells, pranlukast, drug repositioning,
triple-negative breast cancer cells
Introduction
Breast cancer has the highest global incidence in women.1 It is estimated that over
1,670,000 new breast cancer patients are diagnosed worldwide each year.2 Despite the
implementation of new targeted therapies and treatments, a high percentage of breast
cancer patients still die due to tumor resistance, recurrence, and metastasis.3 In vivo
data have demonstrated that cancer stem cells (CSCs), a small subset of tumor cells,
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have tumor-initiating and self-renewal capacities.
Accordingly, CSCs mediate the resistance to conventional
therapies, metastasis, and tumor recurrence,4 rendering them
excellent targets for new anticancer treatments.
CD49f (α6 integrin; ITGA6) is a cell surface protein
that forms heterodimers with β1 or β4 integrins, and the
resulting complexes act as laminin-binding receptors.5,6
Hence, CD49f-containing integrins regulate communica-
tion between cancer cells and the microenvironment.
CD49f expression in human breast tumors correlates with
reduced overall and recurrence-free survival rates.7
Accordingly, its inhibition reduces the migration, invasion,
and metastatic potential of breast cancer cells.8–10
CD49f plays a key role in stemness promotion and
maintenance in breast cancer.11,12 CD49f blockade with
antibodies or CD49f knockdown decreases the in vitro
clonogenicity13 and in vivo tumorigenicity12,14 of breast
cancer cells. On the other hand, CD49f is either not
expressed in non-stem breast cancer cells15–17 or expressed
but not essential for their survival.9,10
The key role of CD49f in stemness indicates that it can be
targeted to reduce the breast CSC pool and slow up breast
cancer progression. However, CD49f has not been clinically
targeted, despite the fact that integrin-blocking antibodies, pep-
tides, or small molecules are used to treat various pathologies,
such as thrombosis, osteoporosis, fibrosis, and cancer.18–21
To repurpose drugs as CD49f antagonists, herein we per-
formed consensus molecular docking between the β-subunit-
interacting domain of CD49f and a collection of structures that
are enriched in FDA-approved drugs.22 Five in silico-selected
drugs effectively blocked CD49f, inhibiting the adhesion of
breast cancer cells to laminin. Pranlukast, a reported cysteinyl
leukotriene receptor 1 (CysLTR) antagonist, decreased the clo-
nogenicity of breast cancer cells by mammosphere formation
assay but had no impact on the viability of bulk tumor cells.
Short exposure to pranlukast reduced CD49f-downstream sig-
naling, including Focal Adhesion Kinase (FAK) and phospha-
tidylinositol 3-kinase (PI3K) activation. Pranlukast-treated cells
showed reduced expression of CSC markers and impaired
tumorigenicity in vivo, indicating that this drug decreases the




The primary sequences of CD49f and β1 integrin were obtained
from the Uniprot database (P23229 and P05556, respectively).
Human CD49f 3D model was generated by homology modeling
withModeller 9.1123 using crystallographydata fromProteinData
Bank 4G1M, 4WJK, 4WK0, and 3IJE as templates. The drugg-
ability of the protein pockets was assessed using the
DoGSiteScorer server tool (Hamburg University, Germany).24
A library of 11,421 molecules (FDA-approved, withdrawn, and
experimental drugs) were retrieved from the ZINC InMan subset
of the ZINC12 database (University of California, San
Francisco).22 Auto-DockTools was used to add Gasteiger charges
and polar hydrogens to CD49f and the drugs. Docking was
performed using AutoDock Vina 1.1.225 and AutoDock426 with
a grid box thatwas centered onMet262 in the targetmodel and set
to 17 x 17 x 17 number of points (npts)with 0.375-Å spacing. The
scores were re-evaluated with DSX_08927 to increase the relia-
bility and accuracy of the antagonist selection. The scores from
eachalgorithmwereused togenerateZ-scores, as described.28The
consensus score was the sum of Z-scores.
Compounds
Solutions of pranlukast hemihydrate (Sigma, catalog No P0080),
montelukast sodium hydrate (Sigma, catalog No SML0101), ima-
tinibmesylate (Selleckchem, catalogNoST1571), and bromocrip-
tine (Sigma, catalog No B2134)—dissolved in DMSO—and
zosuquidar (Selleckchem, catalog No S1481)—dissolved in PBS
—werefilter-sterilized and stored at 4°C (montelukast, bromocrip-
tine) or −20°C (pranlukast, imatinib, and zosuquidar) under light-
protected conditions until use.
Cell Culture
The MDA-MB-231 cell line was purchased from ATCC and
grown in Leibovitz’s L-15 medium (Gibco, catalog
Nº 41300021), supplemented with 10% fetal bovine serum
(FBS), in a carbon dioxide (CO2)-free system. We employed
cells from passage 8 to 14. Sublines that stably expressed firefly
luciferase (Luc) under the SOX2 promoter were generated by
cotransfection of SOX2-Luc plasmid29 (donated by Dr. Richard
Pestell, Baruch S. Blumberg Institute, PA, USA) and pNEG-
PG04. The sequence of the promoter was verified using
RVprimer3. Sublines were maintained in RPMI-1640 (Gibco,
catalog Nº 31800014) that was supplemented with 10% FBS
and 0.5 μg/mL puromycin. The MCF-7 cell line (passage 7–9),
obtained from ATCC, was grown in EMEM (ATCC, catalog Nº
302003), supplemented with 10% FBS and 0.01 mg/mL insulin
(Sigma-Aldrich, catalog I3536).
Immunophenotyping
Cells were harvested with TrypLETM Select Enzyme
(Gibco, catalog No 12563011), and 105 cells were stained
Velázquez-Quesada et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
with Alexa Fluor®-647 Rat IgG2a κ isotype control (BD
Pharmigen, catalog No 557857) or Alexa Fluor®-647 Rat
anti-human CD49f (BD Pharmigen, catalog No 562473).
CD44 staining was performed with Brilliant Violet 421
Mouse anti-human CD44 (BD Horizon, catalog No
5628790). Fluorescence was measured by flow cytometry
(Attune NxT, Life Technologies), and the data were ana-
lyzed with FlowJo, version 8.7 (Tree Star Inc.).
Cell Viability
The effects of the drugs on viability were determined in
cells that were in the exponential growth phase by MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay.
The amount of reduced tetrazolium salt was measured
spectrophotometrically at 490 nm (Epoch, Biotek).
Cell Adhesion
Cell adhesion assays were performed as reported.30,31
Briefly, 96-well microplates were coated with 20 μg/mL
cold natural mouse laminin (Invitrogen, catalog No 23017-
015) and incubated overnight at 4°C. The wells were
blocked with 10 mg/mL heat-denatured bovine serum
albumin (BSA) for 1 h at 37°C.
Next, 3 x 105 cells from cultures after 12 h of serum
starvation were preincubated with the selected drugs for 30
min at 37°C with shaking and then placed immediately
into the laminin-coated wells and incubated for 20 min at
37°C. The wells were rinsed with PBS to remove nonad-
herent cells, and the number of viable attached cells was
quantified by MTS reduction. As a control for the specifi-
city of the system, CD49 blocking antibody (clone GoH3;
BD Biosciences, catalog No 562473) was included. The
data were normalized to the signal that was obtained with
the corresponding vehicle-treated cells.
Mammosphere Formation
Mammosphere formation assay was performed as
reported.15,28,32 Briefly, the cells were plated at low density
(100 viable cells per well) on a 96-well ultra-low attachment
plate (Corning Costar) with MammoCult medium and growth
factors (StemCell Technologies, catalog No 05620). The
number of mammospheres with diameter >80 μm was quan-
tified at day 7 by taking micrographs (Eclipse Ti-U micro-
scopy, Nikon) and analyzing them in ImageJ.33 In some
experiments, the drugs were present during the
7-d incubation, whereas in other setups, the cells were pre-
treated for 24 h and the mammospheres were allowed to grow
in drug-free medium. The results are expressed as the percen-
tage of mammospheres with respect to the vehicle control.
Molecular Dynamics
MD simulations were performed with a heterodimeric model
containing the seven-bladed beta-propeller domain of
CD49f and the I-like and hybrid domains of β1 integrin,
using Amber ff99SB force fields and the Amber 12
package.34 The system was solvated using the TIP4P35
water model in a periodic box, followed by the addition of
Na+ and Cl− counterions to neutralize the systems. Ca2+ and
Mg2+ ions were also included in the simulation as they are
required for the proper function of this protein. The best
pranlukast pose on CD49f was selected by clustering analy-
sis of AutoDock4 data and used as a starting pose. Before
the MD simulations, energy minimization and equilibration
of the system were performed at constant temperature (300
K) and pressure (1 atm) using AmberTools. The MD simu-
lations proceeded for 500 ns at the specified pressures and
temperatures. Trajectory snapshots were taken every 10 ps
for analysis. Root-mean-square deviation (RMSD) and
Root-mean-square fluctuation (RMSF) of the backbone in
the docked complex were analyzed in AmberTools 12. The
hydrogen-bond formation between pranlukast and CD49f
residues was determined by the implementation of the
H-bond search module of Pytraj library (https://amber-md.
github.io/pytraj). Interacting residues of the interface
between α and β integrin subunits were determined by the
Residue Interaction Network Generator (RING) server.36
The binding-free energy (ΔG) was calculated on the last
40 ns of the MD simulation using the MM-GBSA method
as implemented in AmberTools 12.37 The calculation of
entropy was not included in our protocol because it is time-
consuming and exhibits a high degree of uncertainty.
Western Blot and
Co-Immunoprecipitation
Cells were lysed in RIPA buffer (50 mM Tris-HCl, 0.1%
SDS, 150 mM NaCl) supplemented with phosphatase inhi-
bitors (2 mM EDTA, 15 mM NaF, 5 mM Na3VO4) and
protease inhibitors (5 μg/mL leupeptin, 1 μg/mL pepstatin,
2 μg/mL aprotinin). Protein concentrations in the lysates
were determined using the Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific, catalog No 23225). Samples
containing 30 µg of total protein were separated by SDS-
PAGE and electroblotted onto PVDF membranes. After
being blocked, the membranes were incubated with anti-
Dovepress Velázquez-Quesada et al
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phospho-FAK (Tyr397; Millipore, catalog No MAB1144),
anti-phospho-AKT (Cell Signaling, catalog No 92755), or
anti-SOX2 (Abcam, catalog No 97959), followed by an
HRP-conjugated secondary antibody. To correct for differ-
ences in the amount of total protein loaded, the same
membranes were stripped and reprobed with anti-FAK
(Santa Cruz Biotechnology, catalog No sc-1688), anti-
AKT (Cell Signaling, catalog No 92725), anti-β-actin
(Santa Cruz Biotechnology, catalog No sc-47778) or anti-
α-tubulin (Santa Cruz Biotechnology, catalog No sc-
398103).
For co-immunoprecipitation assays, samples containing
1mg of protein were incubated overnight at 4°C and constant
agitation with anti-FAK and Protein A-agarose. After rinsing,
the immune complexes were denatured with Laemmli buffer,
subjected to SDS-PAGE, and electroblotted. Membranes
were sequentially probed with anti-PI3K p110α (Santa Cruz
Biotechnology, catalog No SC-293172) and anti-FAK.
Protein bands were detected using SuperSignal West
Femto Maximum Sensitivity Substrate Pierce ECLWestern
Blotting Substrate (Thermo Fisher Scientific, catalog No
34095). Band intensities were measured in ImageJ33 and
data were normalized against the vehicle (DMSO).
SOX2 Promoter Transactivation
MDA-MB-231 cells that stably expressed Luc under the
SOX2 promoter were seeded into 24-well plates and incubated
with drugs for 24 h. Then, the medium was removed, and the
cells were lysed with 1% Triton X-100, 1 mM DTT in GME
buffer for 10 min (room temperature). The homogenates were
transferred to Eppendorf tubes, and 3 volumes of assay buffer
(17 mM K2PO4, 1 mM DTT, and 2 mMATP in GME buffer)
were added. After the addition of luciferin (GOLDBIO, cat-
alog No LUCK-100), Luc activity was quantified as
reported29 (GloMax® 20/20; Promega). Data were normalized
to the fraction of viable cells at each drug concentration.
Limiting-Dilution Xenotransplantation
(LDT)
MDA-MB-231 cells expressing Luc2-eGFP38 were treated
with pranlukast (50 μM) or the corresponding vehicle for 24
h. Cells were detached, suspended in Dulbecco’s PBS, mixed
1:1 with Matrigel® matrix (Corning, catalog No 35621), and
injected immediately into the thoracic mammary fat pad of
7–8-week-old female nu/nu mice (Cinvestav, Mexico). The
tumor formation was examined by palpation at the injection
site and by in vivo bioluminescence imaging as reported38 on
an IVIS XR system (Caliper Life Sciences). Bioluminescence
data were analyzed using Living Image 3.0 (Caliper Life
Sciences). At day 36 after injection, the mice were euthanized
and necropsied to corroborate the presence of tumors.
Animal procedures were performed per Mexican
guidelines for the production, care, and use of laboratory
animals (NOM-062-ZOO-1999) and the National
Institutes of Health Guide for the Care and Use of
Laboratory Animals. The animal experiments were
approved by the IACUC of the School of Medicine,
UNAM (FMED/CI/JMO/102/2012).
Statistical Analyses
Half-maximal inhibitory concentration (IC50) values were
calculated by non-linear regression. Statistical significance
was determined by one-way ANOVA or Kruskal–Wallis
test. P values ≤0.05 are reported. GraphPad Prism (v6.0)
was used to perform analyses. The estimation of CSC
frequency was performed using ELDA software.39
Results
In silico Selection of CD49f Antagonists
We performed molecular docking using the β1-interacting
domain of CD49f and 11,421 molecules from the InMan
subset of the ZINC12 database. The docking scores obtained
with AutoDock Vina (Suppl. Figure 1A), Autodock (Suppl.
Figure 1B), and their re-evaluation with DSX_089 (Suppl.
Figure 1C–D), were normalized and used to generate
a consensus Z-score (Suppl. Figure 1E). Of the compounds
with lower consensus Z-scores, we selected five drugs with
different reported targets (Suppl. Figure 1F): bromocriptine,
montelukast, pranlukast, zosuquidar, and imatinib.
CD49f Antagonists Decrease Cell
Adhesion to Laminin
For biological validation of our in silico findings, we ana-
lyzed the function of laminin receptors in breast cancer cells
exposed to the drugs. We employed the triple-negative
MDA-MB-231 cell line, which highly expresses CD49f
(Suppl. Figure 2) and can efficiently adhere to laminin.40
We found that >99% of MDA-MB-231 cells have high levels
of membrane CD49f (Figure 1A), as reported.41 We observed
that all selected drugs dose-dependently decreased the MDA-
MB-231 cell adhesion to laminin (Figure 1B–F).
Montelukast, zosuquidar, and pranlukast had IC50 values
between 10 and 30 μM, whereas those of imatinib and
bromocriptine exceeded 50 μM. In these experiments, the
Velázquez-Quesada et al Dovepress
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treatment of cells with a CD49f-blocking monoclonal anti-
body (clone GoH3) abolished cell adhesion (open circles in
Figure 1B– F), demonstrating that laminin adhesion of
MDA-MB-231 cells depends on CD49f-containing integrins.
Pranlukast Impairs Mammosphere
Formation Independently of Its Cytotoxic
Effect
To determine the impact of CD49f antagonists on the fraction
of stem/progenitor cells, we performed mammosphere assays.
Continuous exposure of cells to bromocriptine, montelukast,
pranlukast, zosuquidar, or imatinib significantly reduced the
number of mammospheres formed by MDA-MB-231 cells
(Figure 2A and Suppl. Figure 3). For comparison, we analyzed
the cytotoxic effect of the drugs on tumor-bulk cells by per-
forming cell viability assays in 2D cultures (Figure 2B). In
these assays, only zosuquidar had an IC50 < 10 μM, and thus,
only this drug should be classified as cytotoxic per NCI
guidelines.42
The best candidate for further analysis was chosen by
calculating a ratio between the IC50 values from both assays
(Table 1). The concentration of pranlukast that was required
to reduce the viability of 2D cultures was 10 times higher
than what was needed to reduce clonogenicity, suggesting
that this drug selectively affects breast CSCs.
Pranlukast Binding Induces Destabilization
of α6β1 Heterodimer
To analyze the mechanism involved in pranlukast effects, we
performedmolecular dynamics (MD) simulations studying the
drug´s interaction with a heterodimeric model composed of
the seven-bladed beta-propeller domain of CD49f and the
I-like and hybrid domains of β1 integrin. Root-mean-square
deviation (RMSD) analysis showed that the heterodimeric
complexes, with and without drug, reached equilibrium at
~150 ns (Figure 3A). Therefore, further analyses were per-
formed with the 150 to 500 ns time frame. Pranlukast binding
to CD49f was stable during the MD simulation. The drug–
CD49f interaction was mediated by hydrophobic contacts, pi-
pi stacking (Figure 3B), and hydrogen bonds (Figure 3C). We
identified up to two simultaneous hydrogen bonds that
involved Asn681, His702 or Ile703 in our model, which
correspond to Asn300, His321 and Ile322 in the primary
sequence of CD49f. The analysis of the root-mean-square
fluctuation (RMSF) of backbone alpha carbons showed that
pranlukast restricted the main backbone fluctuations of the
propeller domain of CD49f (Figure 3D). Pranlukast induced
conformational changes in the CD49f-binding site, reducing
the fluctuations of the loop connecting C and D sheets of blade
5, but also in other regions of the protein that participate in the
binding to the β subunit, such as in blades 2 and 3 (Figure 3E).
Analysis of the α/β interface showed changes in the contacting
Figure 1 Effects of CD49f antagonists on CD49f adhesion to laminin. (A) Expression of CD49f in MDA-MB-231 cell line (gray histogram), assessed by FACS, versus its
isotype control (white histogram). (B–F) Impact of selected compounds on MDA-MB-231 cell line adhesion to laminin. Graphs show the mean ± SEM of three independent
experiments for bromocriptine (B), montelukast (C), pranlukast (D), zosuquidar (E), and imatinib (F). Half-maximal inhibitory concentration (IC50) values were calculated
by nonlinear regression and reported in Table 1. Statistical significance was determined by Dunnett´s test; P value <0.05 (*), <0.01 (**), <0.0001 (****).
Dovepress Velázquez-Quesada et al
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residues. For example, the surface on the I-like domain of β1
integrin had a different pattern of contacting residues in the
presence of pranlukast (Figure 3F). Furthermore, the binding-
free energy between the propeller domain of CD49f and the β1
subunit increases in presence of pranlukast (Figure 3G), indi-
cating that the drug decreases the affinity between the sub-
units. This observation is consistent with the restricted
conformational dynamics of the complex induced by
pranlukast.
Pranlukast Effect on Other Laminin
Receptors
To assess the specificity of pranlukast on CD49f, we performed
laminin adhesion assays using MCF-7 breast cancer cells.
Despite their low CD49f expression,41 and Suppl. Figure 4A
the cells efficiently adhered to laminin (Suppl. Figure 4B) as
previously reported.43,44 The addition of pranlukast (50 μM)did
not affect the adhesion of MCF-7 cells to laminin (Suppl.
Figure 4C), suggesting that the drug does not change the
activity of other laminin receptors.
Pranlukast Affects CD49f-Downstream
Signaling
The effects of pranlukast on CD49f-mediated signaling were
evaluatedusingadherent culturesofMDA-MB-231cells exposed
for 24 h. Subtoxic concentrations of pranlukast (≤50 μM; Suppl.
Figure 5) decreased the integrin-dependent autophosphorylation
of FAK at Tyr397. Pranlukast 12.5 μM reduced FAK phosphor-
ylation without changes in total FAK, but 50 μM reduced both
FAK phosphorylation as well as FAK expression (Figure 4A).
Most importantly, blockage of CD49fwith a specificmonoclonal
antibody only decreased FAKphosphorylation to 40%of control,
indicating that in MDA-MB-231 cells, FAK activation is also
mediated by other integrins, as reported.45
CD49f enhances radioresistance in breast cancer cells
through the activation of the FAK-PI3K-AKT signaling
pathway.41 Thus, we studied the effect of pranlukast on the
activation of FAK-downstream effectors. Pranlukast impaired
the activity of PI3K, as demonstrated by the reduced phosphor-
ylation of the PI3K-target AKT in cells treated with the drug
(Figure 4B). The treatment also reduced the association of PI3K
with FAK in co-immunoprecipitation assays (Figure 4C).
Together, these results demonstrate that pranlukast affects the
FAK/PI3K signal transduction pathway, supporting the idea that
the drug impairs the function of CD49f-containing integrins.
Figure 2 Selection of drugs with the highest CSC selectivity. Effect of CD49f antagonists on MDA-MB-231 mammosphere formation (A) and cell viability at 48 h, assessed
by MTS assay (B). Graphs show mean ± SEM of three independent experiments. Half-maximal inhibitory concentration (IC50) values were calculated by nonlinear regression
and reported in Table 1. Statistical significance was determined by Dunnett´s test; P value <0.05 (*), <0.01 (**), <0.001 (***), <0.0001 (****).
Table 1 Calculated IC50 Values from Viability or Mammosphere









Bromocriptine 61.1 μM 34.9 μM 0.57
Montelukast 48.4 μM 52.6 μM 1.09
Pranlukast 9.5 μM >100 μM >10.53
Zosuquidar 4.7 μM 9.1 μM 1.96
Imatinib 7.5 μM 36.5 μM 4.86
Note: Drug with higher ratio (bold) was selected for further studies.
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Pranlukast Affects Stemness and Reduces
the CSC Frequency
The effects of pranlukast on stemness were evaluated after
exposing adherent cultures of MDA-MB-231 cells for 24
h to the drug (Figure 5A). Preincubation of MDA-MB-231
cells with 50 μM of pranlukast significantly reduced the
mammosphere-forming efficiency under drug-free condi-
tions (Figure 5B). Further, pranlukast significantly reduced
the expression of the CSC marker CD44 (Figure 5C) and
the pluripotency protein SOX2 (Figure 5D), as well as
SOX2 promoter transactivation (Figure 5E).
The effect of pranlukast on tumor onset was assessed
by limiting dilution xenotransplantation. We injected
groups of nu/nu mice with different numbers of vehicle-
or pranlukast-treated cells. The bioluminescence at time 0
showed that paired groups were homogeneously injected
with live cells (P>0.05; Student´s t-test). The fraction of
tumor-free mice in each group was quantified 5 weeks
later (Figure 5F). For example, the injection of 2000
pranlukast-treated cells generated tumors in 3 out of 8
mice, compared with 6 out of 8 tumors produced by
vehicle-treated cells (Figure 5G). The limiting dilution
Figure 3 Moleculardynamics analysis of pranlukast interactionwithα6β1 integrin. (A)Root-mean-squaredeviation (RMSD)versus timeplot for thebackboneatoms in theabsence (black line)or
in the presence (red line) of pranlukast. (B) 2D representation of pranlukast-CD49f interactions. Residues in the binding site are represented as follows: acidic residues in orange, basic residues in
violet, polar residues in blue, and hydrophobic residues in green. Green lines connecting residues to pranlukast indicate pi–pi stacking interactions and grey “clouds” on drug atoms indicate the
solvent-exposed surface area. (C) Time evolution of the number of intermolecular hydrogen bonds formed between CD49f and pranlukast. (D) Root-mean-square fluctuation (RMSF) versus
residueposition for thebackboneatomsof the targetheterodimer in the absence (black line)or in thepresenceofpranlukast (red line). (E)Overlapof3Dmodelsof thepropellerdomainofCD49f
withorwithoutpranlukast (in red spheres).Regionswithnochanges inbackboneatomsbetweenmodels are inblue,whereas regionswith significant changes are in green forpranlukast-boundand
orange for drug-free models, respectively. The number of the blades [B1–7] within the seven-bladed domain and the order of the beta-sheets [A–D] within blades is annotated. (F) Surface
representation of the interface of β1 integrin with or without pranlukast. Residues making hydrophobic contacts or hydrogen bonds with CD49f are shown in yellow and green, respectively. (G)
Binding-free energy calculated fromMDsimulation (ΔGbind, calc).ΔGbind, calc for the drug free- and pranlukast bound-complexes (bold values)were calculated considering the energy contributed by
electrostatic (ΔGele), van derWaals (ΔGvdw), hydrophobic (ΔGnonpol), and polar (ΔGpol) forces. The values in parenthesis correspond to the standard error of mean.
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analysis of pooled results showed a significant 3.7-fold
reduction in the frequency of tumor-initiating cells after
pranlukast treatment (Figure 5H). Thus, pranlukast
reduced stemness signaling and impaired cellular functions
that define CSC, demonstrating that it declines the CSC
population.
Discussion
Integrin dimerization is crucial for the generation of its
ligand-binding domain and, consequently, for integrin acti-
vation and clustering.20,21 Disruption of dimerization by
peptides or monoclonal antibodies blocks integrin cluster-
ing and integrin-mediated adhesion.46–48 Targeting pro-
tein–protein interactions (PPIs) with small compounds
has emerged as a novel and viable approach in modern
drug discovery.49 Thus, we hypothesized that altering PPIs
in CD49f-containing integrins by using pharmochemicals
would impair their activity.
By molecular docking, we identified 20 compounds
with high binding potential to a druggable pocket within
the seven-bladed beta-propeller domain of CD49f. Of
these potential antagonists, we focused on five drugs
with known pharmacokinetics and pharmacodynamics.
Analyzing new biological activities of drugs with reported
therapeutic use (drug repurposing) is a strategy that
reduces the time between the discovery of a new applica-
tion and clinical translation.50,51 Our team used a similar
strategy to identify etoposide as an antagonist of CD44.28
The five selected drugs – bromocriptine, montelukast,
pranlukast, zosuqidar, and imatinib – inhibited the adhe-
sion of CD49f+ breast cancer cells to laminin with various
potencies. Our data showed that the adhesion of MDA-MB
-231 cells highly depends on CD49f, as demonstrated by
the use of a monoclonal anti-CD49f. These results indicate
that the selected pocket has functional relevance and could
be used to design new antagonists for CD49f or other
homologous integrins.
CD49f is central in maintaining the stemness7,11,12,14,17
but is dispensable for the survival of non-CSCs in vitro.9,10
Consequently, CD49f blockade is expected to affect clo-
nogenicity with a minor impact on global cell viability.
Hence, our subsequent screening compared the effect of
Figure 4 Effect of pranlukast on FAK signaling. (A) Representative Western blot evaluating the Tyr397 phosphorylation of FAK (pFAK) and the corresponding analysis of the pFAK/
FAK ratio from three independent experiments. (B) Representative Western blot analyzing the phosphorylation of the PI3K substrate AKTand the densitometric analysis from four
independent experiments. The PI3K inhibitor LY294002 [LY; 5 μM] was employed as a control. (C) Western blot against PI3K or FAK in samples immunoprecipitated with anti-FAK.
Graph shows densitometric analysis from four independent experiments. All statistical analyses were performed using Dunnett’s test; P value <0.05 (*), <0.01 (**).
Abbreviation: AU, arbitrary units.
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Figure 5 Effect of pranlukast on breast cancer cell stemness. (A) Experimental strategy. (B) Viable MDA-MB-231 cells previously exposed to pranlukast for 24 h were seeded to test their
capacity to formmammospheres in the absence of the drug. Graphs show themean numberofmammospheres ± SD from three independent experiments. (C) Analysis of CD44 expression by
flow cytometry. The annotated percentages correspond to CD44hi population. A representative experiment from 2 is shown. (D) Representative Western blot analyzing SOX2 expression.
Graph represents the mean ± SEM from three independent experiments. (E) Analysis of SOX2 promoter transactivation by luciferase assay. Values are mean ± SEM from four independent
experiments. Scheme above graph shows the promoter size in the construct. Statistical significance in (B), (D), and (E) was determined by Dunnett´s test; P value <0.05 (*), <0.01 (**). AU:
arbitrary units. (F) Tumor formation in nude mice injected with 2000 cells in the vehicle (upper row) or pranlukast (lower row) groups. The presence of tumors was evaluated 36 days
postinjection by bioluminescence quantification and dissection. Insets show the dissected tumors; scale bar = 3 mm. (G) Tumor incidence in groups of mice xenotransplanted with vehicle- or
pranlukast-treated cells. (H) Log-fraction plot of the limiting dilutionmodel fitted to the data shown in (E). TheCSC frequency and the corresponding 95% confidence intervals (dotted lines and
fractions in parenthesis) were calculated using ELDA software. The CSC frequency was significantly different among treatments (P=0.0044; chi-square test).
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each drug on mammosphere formation, a functional esti-
mation of the number of CSCs,15,52 versus its effect on the
viability of adherent cultures, which are enriched in non-
stem cells.53,54 Pranlukast decreased the number of mam-
mospheres with limited cytotoxicity to adherent cultures,
supporting that it selectively targets the CSC pool.
Pranlukast binding mode to CD49f was further character-
ized by MD simulations. Those experiments were performed
with a heterodimeric model that included key domains for the
ligand-binding activity of integrins.21,46,55 Pranlukast stably
bound to CD49f in a region that includes residues that parti-
cipate in or lie near the reported β-subunit interaction site in
homologous proteins. In the αV integrin, the template used
for our CD49f model, the contacting residues with the β3
subunit reside primarily in blades 3–5 of the seven-bladed
beta-propeller domain.55 Accordingly, pranlukast binding to
CD49f reduced the affinity for the β subunit. Furthermore,
our results suggest that pranlukast constrains the conforma-
tional dynamics of the protein, which is crucial to regulate the
activation state of the heterodimer.46
We also analyzed the effect of pranlukast in CD49f-
downstream signaling using MDA-MB-231 cells. FAK,
a non-receptor tyrosine kinase, mediates signal transduction
by CD49f12 and has been associated with aggressiveness in
triple-negative breast tumors.56 FAK ablation in mammary
epithelial cells delays tumorigenesis and reduces the pool of
CSC in mammary tumors.57 Fittingly, FAK inhibition blocks
metastatic ability and stemness in triple-negative breast can-
cer cells.58 We found that pranlukast decreased the integrin-
dependent autophosphorylation of FAK at Tyr397, which is
a surrogate measurement of FAK activation.59 CD49f-FAK
activity stimulates the PI3K/AKT pathway leading to its
hyperactivation in triple-negative tumors60 and in breast
CSCs.61 We showed that pranlukast reduced FAK-PI3K
interaction and AKT phosphorylation, corroborating that
CD49f-activated signaling was impaired by the drug.
Previous studies have demonstrated that PI3K/AKT
blockage induces CSC-differentiation in breast cancer
cells.62 Thus, we studied whether pranlukast effects on
CSC were reversible using an experimental design reported
by Gupta and colleagues.63 Short-term exposure to pranlu-
kast reduced the fraction of mammosphere-initiating cells in
drug-free cultures as well as the number of tumor-initiating
cells in vivo. These changes in the CSC pool were corrobo-
rated by quantifying the expression of two proteins that
participate in the maintenance of stemness, expression of
EMT markers, invasiveness, and metastatic capability:
SOX264–66 and CD44.67 SOX2 is a target of CD49f-
activated signaling11 and its downregulation is sufficient to
diminish the pool of breast CSCs.66,68,69 Pranlukast reduced
SOX2 protein level with a modest decrease in SOX2 promo-
ter transactivation, suggesting that the drug affects the post-
translational modifications and the stability of the protein.
SOX2 expression positively correlates with that of CD44 in
clinical samples;70 accordingly, we found a reduction of the
CD44hi population in pranlukast-treated cells. Since SOX2
and CD44 expression induce chemoresistance in MDA-MB
-231 cells,71 future studies would analyze the effect of pran-
lukast in the response to cytotoxic drugs.
Pranlukast, like montelukast and zafirlukast, belongs to the
group of CysLTR antagonists, which are used to treat chronic
bronchial asthma.72 Although pranlukast and montelukast
were selected as potential CD49f antagonists by our in silico
screen, our results show that they have dissimilar pharmaco-
logical behaviors, as described.72 For example, both drugs
inhibit CysLTR1-mediated lung colonization by cancer cells,
but only pranlukast impairs capillary permeability and cancer
cell extravasation in the brain.73 Further, pranlukast was
recently reported to act as an agonist of Raf1 kinase inhibitory
protein,74 which is usually absent in metastatic cancer cells
and is considered a metastasis suppressor.75 These data sug-
gest that pranlukast can target multiple proteins, andwe hereby
report that CD49f should be considered one of such targets.
Conclusions
Our results identified pranlukast, a drug that is adminis-
tered to asthmatic patients, as a CD49f-blocking agent
with functional effects on the breast CSC pool, likely
caused by altered FAK- and SOX2-signaling. Because
the pharmacokinetics and toxicology of this drug are
known, we recommend evaluating pranlukast as an adju-
vant therapy for breast cancer patients to reduce drug
resistance and tumor recurrence.
Abbreviations
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